Introduction To date, there is solid evidence from randomized controlled trials (RCTs)
supporting the rationale for withdrawal from inhaled corticosteroids (ICSs) in most patients …

International guidance on chronic obstructive pulmonary disease (COPD) management
recommends the use of inhaled corticosteroids (ICS) in those patients at increased …

Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend limiting the use of inhaled corticosteroids (ICS) to patients with more severe …

Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid
(ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative …

Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …

Introduction: Current guidelines recommend the use of inhaled long-acting bronchodilators,
inhaled corticosteroids (ICSs) and their combinations for maintenance treatment of moderate …

The use of inhaled corticosteroids (ICS) in the treatment of chronic obstructive pulmonary
disease (COPD) has been widely debated [1–3]. Treatment guidelines have suggested that …

While chronic obstructive pulmonary disease (COPD) continues to be a major cause of
morbidity and mortality, pharmacological therapy has a definite benefit on symptoms as well …

Chronic obstructive pulmonary disease (COPD) is common and preventable. The long-term
safety of inhaled corticosteroid (ICS) use in COPD is still unclear and requires further …

Background Inhaled corticosteroid (ICS) therapy has been demonstrated to reduce the risk
of COPD exacerbations. It should only be prescribed to COPD patients who are not …